Janet Davison Rowley (1925–2013) was an American medical geneticist whose research established that chromosomal abnormalities can be the direct cause of human cancers. Her work provided clear evidence that specific translocations — rearrangements of parts between chromosomes — underlie certain forms of leukemia and helped shift cancer biology toward a genetic and molecular framework.
Background and career
Rowley trained and worked in clinical and laboratory settings, combining diagnostic cytogenetics with patient-focused research. She spent much of her career at institutions associated with clinical medicine, where she taught and mentored generations of physicians and scientists. For an overview of her life and career see her biographical profile.
Key discovery and scientific impact
Across careful chromosome analyses, Rowley identified that a recurring translocation was linked to chronic myelogenous leukemia and that analogous chromosomal rearrangements occurred in other blood cancers. This finding showed that cancer can result from inheritable changes in chromosomal structure rather than only from external agents. Her insights paved the way for molecular characterization of cancer-driving genes and ultimately for targeted therapies that act on the specific abnormal proteins produced by those genetic changes. More on her influence in the study of leukemia and broader cancer research can be found in scientific retrospectives.
Contributions, honors, and recognition
Rowley combined laboratory observation with clinical relevance, and her work received wide recognition. Notable aspects of her legacy include:
- Demonstrating that chromosomal translocations can initiate human malignancy.
- Helping to establish the rationale for molecularly targeted cancer drugs that inhibit products of fusion genes.
- Receiving many major scientific honors and national awards in recognition of her contributions to medicine and genetics.
Her career is often cited as a turning point: where cytogenetics moved from descriptive charts of chromosomes to a mechanistic understanding of how chromosomal changes produce oncogenes and drive disease progression.
Legacy and later life
Rowley continued to influence cancer genetics through research, mentorship, and public engagement. Her discoveries are taught in medical and biological curricula and remain foundational to precision oncology approaches that match therapies to genetic alterations. She died in 2013 from complications of ovarian cancer, and her work continues to inform diagnosis, research, and treatment strategies worldwide.